- Infectious diseases are a leading cause of death globally. Roche is committed to reducing the burden of infectious diseases through effective testing, monitoring and management.
- These will be the first tests launched for use on the new cobas® 5800 System to support patient management of human immunodeficiency virus, Hepatitis B and C virus.
- In addition, the launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs)
- This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the first infectious disease tests on the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas® HIV-1, cobas® HBV, cobas® HCV, cobas® HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardised performance and efficiencies across low, medium and high volume molecular laboratory testing needs.
Roche offers a comprehensive portfolio of infectious disease tests along the continuum of care, enabling laboratories to provide the right information, from screening and diagnosis, for patient management and treatment monitoring.
said Cindy Perettie, Head of the Molecular Lab Customer Area, Roche Diagnostics.
We are pleased that we can increase access to accurate, timely and reliable diagnostics with our first tests on the cobas® 5800 System to patients and their healthcare teams to meet evolving testing demands.
The cobas® 5800 System, a compact new addition to the Roche Diagnostics Molecular Work Area, is built upon the innovation of the cobas® 6800 and 8800 Systems, making molecular testing accessible to more patients around the world.
The cobas® 5800 System will offer the same menu as the cobas® 6800 and 8800 Systems. Roche is pursuing CE approval for continued menu expansion on the cobas® 5800 System, including cobas® SARS-CoV-2, through early-to-mid 2022. Roche anticipates tests to be available beyond CE markets in additional countries in 2022.